We are live on ! Find out more
SLXP

SALIX PHARMACEUTICALS LTD DEL
SLXP

Delisted

SLXP was delisted on the 31st of March, 2015.

304 hedge funds and large institutions have $6.82B invested in SALIX PHARMACEUTICALS LTD DEL in 2014 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 110 increasing their positions, 98 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

359% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 17

173% more call options, than puts

Call options by funds: $81.1M | Put options by funds: $29.7M

67% more funds holding in top 10

Funds holding in top 10: 610 (+4)

24% more funds holding

Funds holding: 246304 (+58)

12% more repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 98

8% more capital invested

Capital invested by funds: $6.3B → $6.82B (+$520M)

Holders
304
Holders Change
+58
Holders Change %
+23.58%
% of All Funds
8.78%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.29%
New
78
Increased
110
Reduced
98
Closed
17
Calls
$81.1M
Puts
$29.7M
Net Calls
+$51.5M
Net Calls Change
+$4.64M
Name Holding Trade Value Shares
Change
Change in
Stake
Citigroup
226
Citigroup
New York
$698K -$2M -19,491 -74%
PCM
227
Prelude Capital Management
New York
$697K +$442K +4,315 +179%
SGH
228
Schonfeld Group Holdings
New York
$693K +$684K +6,684 New
KBC Group
229
KBC Group
Belgium
$645K
WAM
230
World Asset Management
Michigan
$639K +$3.17K +31 +0.5%
QC
231
QCM Cayman
Texas
$578K +$571K +5,580 New
Calamos Advisors
232
Calamos Advisors
Illinois
$552K +$545K +5,325 New
EMG
233
Ellington Management Group
Connecticut
$539K +$287K +2,800 +117%
AA
234
ALPS Advisors
Colorado
$528K +$522K +5,100 New
PAG
235
Private Advisor Group
New Jersey
$510K +$275K +2,686 +120%
WB
236
WesBanco Bank
West Virginia
$508K -$61.4K -600 -11%
Thrivent Financial for Lutherans
237
Thrivent Financial for Lutherans
Minnesota
$508K +$10.2K +100 +2%
ACI
238
AMP Capital Investors
Australia
$499K
AAM
239
Advisors Asset Management
Colorado
$499K +$38.6K +377 +9%
BFS
240
Bradley Foster & Sargent
Connecticut
$492K +$486K +4,745 New
RFC
241
Russell Frank Company
Washington
$488K -$543K -5,306 -53%
PCP
242
Perimeter Capital Partners
Georgia
$475K +$469K +4,581 New
GF
243
Gerstein Fisher
New York
$473K +$388K +3,791 +490%
Group One Trading
244
Group One Trading
Illinois
$463K +$117K +1,143 +34%
AG
245
Aperio Group
California
$446K +$441K +4,308 New
PI
246
Placemark Investments
Illinois
$433K +$41.8K +408 +11%
Truist Financial
247
Truist Financial
North Carolina
$419K -$267K -2,603 -39%
BPGAM
248
BTG Pactual Global Asset Management
Bermuda
$403K +$398K +3,890 New
FP
249
Foundry Partners
Minnesota
$399K +$395K +3,855 New
WSTAM
250
Wilbanks Smith & Thomas Asset Management
Virginia
$383K

SLXP Hedge Fund Activity: Q1 2014 in Review

304 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q1 2014, worth a combined $6.82B — up 8.3% from $6.3B a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new SLXP positions and 17 closed out — a net gain of 61 holders — while 110 added to existing stakes and 98 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $159M. The largest seller was TIAA CREF Investment Management, cutting an estimated $145M.

  • 304 institutional investors held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q1 2014, up from 246 in Q4 2013.
  • Funds reported $6.82B of SALIX PHARMACEUTICALS LTD DEL stock for Q1 2014, up 8.3% quarter-over-quarter.
  • 78 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q1 2014 and 17 closed out, a net change of +61 holders.
  • The largest SALIX PHARMACEUTICALS LTD DEL buyer in Q1 2014 was Viking Global Investors, an estimated $159M added.
  • The largest SALIX PHARMACEUTICALS LTD DEL seller in Q1 2014 was TIAA CREF Investment Management, an estimated $145M sold.

Based on aggregated 13F filings for Q1 2014.